Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1821
Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections
Published 2025“…The unexpected SAR of compound <b>15</b> can be explained by computational modeling. We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”
-
1822
-
1823
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
1824
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
1825
-
1826
-
1827
-
1828
-
1829
Shortlisted PTB-related drugs after manual inspection and applying Lipinski’s rule of 5 screening.
Published 2023Subjects: -
1830
-
1831
-
1832
-
1833
-
1834
-
1835
-
1836
-
1837
-
1838
S2 File -
Published 2023“…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”
-
1839
S1 File -
Published 2023“…This initial increase and subsequent decrease in K6 and FCV-19S were more prominent in individuals with high trait anxiety (K6: B = 1.55, 95% CI = 1.18 to 1.91; FCV-19S: B = 4.27, 95% CI = 2.50 to 6.04) and in occupations other than physicians or nurses. …”
-
1840